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indicating a different mechanism from AMD. The primary mechanism of action of 5a was to arrest the
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chlorobenzyl sophoridinic derivatives with a tricyclic scaffold to be a new class of promising antitumor
agents with an advantage of inhibiting drug-resistant cancer cells.
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12-N-p-Chlorobenzyl sophoridinol derivatives as anticancer agents 2231. Introduction
Several quinolizidine alkaloids extracted from Chinese herb Kushen
have demonstrated potential antitumor activity1–4. Sophori-
dine (1, Fig. 1), the main active ingredient of Kushen extracts,
was approved by the Chinese FDA to treat malignant neoplasm in
20055,6. Its mechanism is to inhibit the DNA topoisomerase I (topo
I) activity and induce cell cycle arrest at the G0/G1 phase7–9. From
compound 1, as depicted in Fig. 1, we have successfully identiﬁed
that 12-N-substitued sophoridinol derivatives were a promising class
of anticancer agents with a novel chemical scaffold and ideal
druggable parameters10,11. A representative compound, 12-N-p-
chlorobenzyl sophoridinol (2, Fig. 1) displayed a reasonable
antiproliferative activity with an IC50 of 9.3 μmol/L, much better
than that of the parent 1 (480 μmol/L)10. Furthermore, it has a
couple of advantages such as special scaffold, ﬂexibility structure,
high solubility and good safety proﬁles. In addition, it has an
excellent potential for further chemical modiﬁcations and
optimization10,11.
The previous structure–activity relationship (SAR) revealed that
12-N-p-cholobenzyl substituent was beneﬁcial for the antitumor
activity10. Thus, taking compound 2 as a lead, SAR investigationFigure 1 Chemical structures of sophoridine (1) 12-N-p-cholobenzyl
Scheme 1 Reagents and conditions: (a) HCl, reﬂux, 6 h; CH3OH, r.t., 5–6
reﬂux, 4 h, in 2 steps; (c) R2MgBr (1.0 equiv.), THF, r.t., 7 h; (d) R2MgBwas continuously developed on the variations of 30-CH2OH at the
11–side chain in an effort to discover more potent antitumor
candidates. In the present study, as illustrated in Fig. 1, the 12-N-p-
cholobenzyl was retained as a required group for activity, and
30-CH2OH at 11–attachment was replaced with various substitu-
ents and different sophoridinic derivatives were produced. Based
on this strategy, a series of sophoridinic ketone, alkene, imine and
amine analogs were then constructed and measured. Herein,
presented in this study were the synthesis, antitumor assessment,
SAR analysis and primary mechanism of action of the representa-
tive compounds.2. Results and discussion
2.1. Synthetic routes
The synthesis of all the newly synthesized compounds was
respectively described in Schemes 1 and 2. Each target compound
was prepared using commercially available 1 with purity over 98%
as the starting material, which was purchased from the Yanchi
Dushun Biological and Chemical Co., Ltd. (Shanxi, China).sophoridinol (2) and the structural fragments in 2 to be modiﬁed.
h, in 2 steps; (b) R1CHO, TEA, 1,2-dichloroethane, reﬂux, 4 h; STB,
r (excessive), THF, reﬂux, 7 h; (e) hydrochloride/ether, r.t., 4 h.
Scheme 2 Reagents and conditions: (a) LiAlH4, THF, r.t.; (b) DMSO, (COCl)2, TEA, DCM, –78 1C, 1 h; (c) HCl/MeOH, r.t., 10 min; (d)
NH2OH.HCl, 20% NaOH, r.t., 12 h; (e) methyl benzenesulfonate, THF, r.t.; (f) R2NH2, MeOH, reﬂux, 4 h; (g) NaBH3CN, MeOH, reﬂux, 4 h.
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sophoridinic ketones 5a–b and 12-N-p-cholobenzyl sophoridinic
alkenes 7a–b was displayed in Scheme 1. The intermediate 3 was
obtained through hydrolysis and esterization of 1 in an overall
yield of 95%10,11. Then the condensation of 3 with 4-
chlorobenzaldehyde followed by the reduction with sodium
triacetoxyborohydride (STB) afforded the key intermediate 4 in
53% yield12. The nucleophilic-addition reaction of 4 with one
molar equivalent of p-Cl-PhMgBr and p-F-PhMgBr in dry THF at
room temperature provided products 5a–b with yields of
61%–62%13, while the reaction of 4 with excessive amount of
Grignard reagents at reﬂux temperature generated tertiary alcohols
6a–c in 45%–58% yields, which were dehydrated under acidic
conditions to give the target alkenes 7a–b with yields of 32%–40%.
As illustrated in Scheme 2, the reduction of 4 in the presence of
LiAlH4 generated sophoridinol 8 in 86% yield, which was
converted to sophoridinic aldehyde 9 through a Swern oxidation
reaction in 56% yield14. The aldol condensation of 9 in
HCl/CH3OH afforded hemiacetal 10 at room temperature with
the yield of 67%, while the condensation of 9 with hydroxylamine
hydrochloride afforded hydroxyl oxime 11 in a 72% yield, which
went through a methyl etheriﬁcation to give the oxime ether 12 in
57% yield. The sophoridinic imines 13a–c were obtained via the
condensation of 9 and three amines, which were then reduced by
sodium cyanoborohydride (NaBH3CN) to afford 14a–b in good
yields. All desired products were puriﬁed by ﬂash chromatography
using CH2Cl2/CH3OH as the gradient eluent.2.2. SAR analysis for antitumor activity
All the target compounds were evaluated for their cytotoxic
activity in human HepG2 hepatoma cell line using Taxol as
a positive control using the MTT assay15. Structures of the
11-sophoridinic derivatives and their anti-proliferative activity
were shown in Table 1. The ClogP values were calculated by
ChemBioOfﬁce software (Version 12.0).
Taking compound 2 as a lead, the SAR investigation was
mainly focused on the variation of 3'-CH2OH at the 11–side chain
with 12-N-p-cholobenzyl as a required group for antitumor
activity. Firstly, in replacing the CH2OH group with ketones, the
resultant compounds 5a–b with higher lipophilicity (ClogP47.0)
displayed improved cytotoxic activity with the IC50 values of
4.9 μmol/L and 4.0 μmol/L, respectively. Introduction of two
methyl groups on the α-carbon adjacent to the hydroxy group led
to a tertiary butyric alcohol 6a, which showed a decreased activity
with an IC50 value of 16.3 μmol/L. The replacement of 30-CH2OH
with an alkene group on the 3'-position created more lipophilic
7a–b, which showed signiﬁcant improvement on the antiprolifera-
tive activity with the IC50 values of 4.3 and 3.8 μmol/L,
respectively, much better than that of 2 and Taxol. The results
suggested that a higher ClogP values might be beneﬁcial for good
potency against cancer.
Secondly, the generated hemiacetal 10, hydroxyl oxime 11,
oxime ether 12 and imines 13a–c abolished cytotoxic activity
partially or completely with IC50 between 11.8 and 450 μmol/L.
Table 1 SAR of the target compounds for their anti-
proliferative activities in HepG2 cells.
Compd. R IC50 (μmol/L) ClogP
2 9.370.4 4.5
5a 4.971.2 7.1
5b 4.070.9 7.0
6a 16.372.8 5.9
7a 4.371.3 10.0
7b 3.871.0 8.0
10 17.372.1 4.5
11 11.271.2 4.6
12 450 4.8
13a 11.870.7 4.9
14a 4.370.1 7.6
14b 5.470.2 4.5
Taxol 15.672.3 4.7
Figure 2 IC50 (μmol/L) value comparison of 5a and 7b in MCF-7
and MCF-7/AMD breast carcinoma cell lines.
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showed a signiﬁcantly improved activity with IC50 values of
4.3 and 5.4 μmol/L, respectively. It seemed that the introduction of
a suitable methyleneamine group on the 30-position might greatly
enhance the activity against cancer.
Considering their potent anticancer effects as well as reasonable
ClogP values, compounds 5a and 7b were chosen as the
representative compounds for further investigation.Figure 3 Blockage of cell cycle in HepG2 cells treated without or
with 5a at different concentrations for 24 h.2.3. Anti-resistant tumor effect of 5a and 7b
Evaluation of compounds 5a and 7b against drug-resistant cancer
cell lines were then carried out. We measured their activity against
human wild MCF-7 and adriamycin (AMD)-resistant MCF-7
(MCF-7/AMD) breast carcinoma cells using AMD as a reference
control16. As depicted in Fig. 2, AMD was active against wild type
MCF-7, and completely inactive in the MCF-7/AMD cells.
Meanwhile, compounds 5a and 7b were equipotent or almost
equipotent in both MCF-7 cell lines, suggesting a different mode
of action from AMD. As compound 5a exhibited an equivalent
antiproliferative effect against both MCF-7 cell lines, thus was
selected for the next study.2.4. Mechanism of action of 5a
To verify the possible change of mechanism of action after the
structure modiﬁcations, ﬂow cytometric analysis in the HepG2
cells was conducted. The HepG2 cells were treated for 24 h
without or with 5a at concentrations of 1.25, 2.5 and 5.0 μg/mL,
respectively. As shown in Fig. 3, compound 5a arrested the
HepG2 cells at the G0/G1 phase as anticipated, indicating a similar
mechanism of action to that of its parent compound 111.3. Conclusions
A variety of novel sophoridinic derivatives, such as sophoridinic
ketones, alkenes, imines and amines, were synthesized and evaluated
for their antitumor activity. SAR analysis indicated that the
introduction of a suitable methyl amine group on the 3'-position
could greatly improve the potency. Compounds 5a and 7b exhibited
an equipotent effect in both AMD-susceptible and AMD-resistant
breast carcinoma cells, indicating a different mechanism from AMD.
The mechanism of action of 5a was to arrest the cell cycle at the G0/
G1 phase, consistent with that of 1. The SAR results provided
powerful information for further modiﬁcations and optimization of
this novel scaffold to identify anticancer candidates that might be
active in drug-resistant cancer cells.
4. Experimental section
4.1. Chemistry
Melting point (m.p.) was obtained with a CXM-300 melting point
apparatus and uncorrected. The 1H NMR spectra were performed
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CA, USA) and 13C NMR on a Bruker Avance III 400 spectrometer
in CD3OD or (CD3)2SO, using Me4Si as a internal standard. ESI
high-resolution mass spectra (HR-MS) were recorded on an
Autospec UItima-TOF mass spectrometer (Micromass UK Ltd.,
Manchester, UK). Flash chromatography was performed on a
CombiﬂashRf 200 machine (Teledyne, Nebraska, USA) using
silica gel having particle size of 0.038 mm.
4.1.1. General procedures for the synthesis of compound 5
To a solution of 4 (0.50 g, 1.2 mmol) in anhydrous THF (20 mL),
1 mol/L 4-chlorophenylmagnesium bromide or 4-ﬂuoropheny-
lmagnesium bromide (1.2 mL) was slowly added at 0 1C and then
stirred at room temperature until TLC analysis showed the
completion of the reaction. Then the reaction was quenched by
the addition of saturated ammonium chloride solution (5 mL).
After the solvent was removed by condensation, dichloromethane
(30 mL) was added, and the resultant mixture was washed by
water (20 mL) and brine (20 mL), dried over anhydrous sodium
sulfate, concentrated, and the residue was puriﬁed by ﬂash column
chromatography on silica gel with CH2Cl2/CH3OH as the eluents
to afford target compounds.
4.1.1.1. 12-N-p-Chlorobenzyl sophoridinic-40,4-chlorophenyl ketone
(5a). The title compound was prepared from 4 and 4-
chlorophenylmagnesium bromide using the same manner as described
above. Yield: 62%; white solid; m.p. 83–84 1C; 1H NMR (500 MHz,
DMSO-d6) δ 7.97 (d, J¼8.1 Hz, 2H), 7.60 (d, J¼8.5 Hz, 2H), 7.38–
7.29 (m, 4H), 3.61 (d, J¼14.1 Hz, 1H), 3.54–3.42 (m, 2H), 3.41–3.32
(m, 4H), 3.20–3.08 (m, 1H), 3.06–2.93 (m, 2H), 2.65–2.57 (m, 1H),
2.40–2.25 (m, 2H), 2.25–2.14 (m, 2H), 2.13–2.03 (m, 1H), 1.94–1.74
(m, 3H), 1.73–1.53 (m, 3H), 1.52–1.35 (m, 3H), 1.28–1.14 (m, 1H);
13C NMR (126 MHz, DMSO-d6) δ 198.8, 138.6, 137.9, 135.1, 131.1,
129.8 (2), 129.75 (2), 128.7 (2), 128.1 (2), 62.2, 58.5, 56.8, 51.6, 49.9,
44.1, 38.0, 35.0, 27.3, 26.0, 22.4, 22.2, 21.6, 21.2, 17.6; HR-MS:
Calcd. for C28H34ON2Cl2 [MþH]þ, 485.2121, Found, 485.2123.
4.1.1.2. 12-N-p-Chlorobenzyl sophoridinic-40,4-ﬂuorophenyl ketone
(5b). The title compound was prepared from 4 and
4-ﬂuorophenyl magnesium bromide using the same manner as
described above. Yield: 61%, m.p.: 87–89 1C; 1H NMR (400 MHz,
DMSO-d6) δ 7.98 (d, J¼8.5 Hz, 2H), 7.60 (d, J¼8.5 Hz, 2H), 7.43–
7.20 (m, 4H), 3.74–3.43 (m, 2H), 3.41–3.32 (m, 4H), 3.20–2.87 (m,
5 H), 2.73–2.55 (m, 1H), 2.41–2.26 (m, 2H), 2.27–2.09 (m, 2H),
1.99–1.74 (m, 3 H), 1.74–1.55 (m, 3H), 1.55–1.33 (m, 3H), 1.27–
1.11 (m, 1H); 13C NMR (101 MHz, DMSO-d6) δ 199.3, 139.2,
138.4, 135.7, 131.7, 130.3 (2), 130.3 (2), 129.3 (2), 128.6 (2), 62.8,
59.0, 57.3, 52.2, 50.5, 44.7, 38.5, 35.5, 27.9, 26.5, 23.0, 22.7, 22.2,
21.7, 18.1; HR-MS: Calcd. for C28H34ON2FCl [MþH]þ, 469.2416,
Found, 469.2416.
4.1.2. General procedures for the synthesis of compounds 6 and
7
4.1.2.1. -40,40 dimethyl sophoridinol (6). To a solution of 4
(0.50 g, 1.2 mmol, 1.0 equiv.) in anhydrous THF (20 mL), solu-
tion of methylmagnesium bromide (4.0 equiv.) in THF was slowly
added at 0 1C and then stirred at room temperature until TLC
analysis showed completion of the reaction. Then the reaction was
quenched by the addition of saturated ammonium chloride solution
(5 mL). After the solvent was removed by condensation, dichlor-
omethane (30 mL) was added, and the resultant mixture was
washed by water (20 mL) and brine (20 mL), dried over anhydroussodium sulfate, concentrated, and the residue was puriﬁed by ﬂash
column chromatography on silica gel with CH2Cl2/CH3OH as the
eluents to afford target compound 6. Yield: 45%, m.p.: 91–93 1C;
1H NMR (400 MHz, DMSO-d6) δ 8.28–7.76 (m, 2 H), 7.66–7.42
(m, 2 H), 4.28–4.05 (m, 1 H), 3.89–3.61 (m, 1 H), 3.37–3.02 (m,
5 H), 3.00–2.74 (m, 3 H), 2.76–2.54 (m, 2 H), 2.06–1.79 (m, 5 H),
1.74–1.58 (m, 5 H), 1.60–1.27 (m, 4 H), 1.00–0.76 (m, 6 H); 13C
NMR (101 MHz, DMSO-d6) δ 134.7, 133.0, 132.9 (2), 129.3 (2),
80.6, 60.9, 55.6, 52.0, 51.9, 44.1, 39.4, 34.0, 33.4, 26.0, 25.2,
22.7, 21.7, 21.1, 17.6, 13.0, 9.0 (2); HR-MS: Calcd. for
C24H37ON2Cl [MþH]þ, 405.2667, Found, 405.2677.
4.1.2.2. 12-N-p-Chlorobenzyl-40,40-di-4-ﬂuorophenyl sophoridi-
nene (7a). Compound 7a was obtained from 4-
ﬂuorophenylmagnesium bromide and 4 stirring at reﬂuxing tem-
perature following the similar procedure with 6 and acidiﬁcation by
HCl/diethyl ether as a white solid. Yield: 32%, m.p.: 64–66 1C; 1H
NMR (600 MHz, CD3OD) δ 7.67–7.57 (m, 2H), 7.55–7.48 (m, 1H),
7.45–7.25 (m, 3H), 7.20–7.03 (m, 6H), 4.59–4.39 (m, 1H), 4.41–
4.16 (m, 1H), 3.97–3.79 (m, 1H), 3.66–3.49 (m, 1H), 3.49–3.33 (m,
3H), 3.21–3.02 (m, 2H), 3.00–2.77 (m, 2H), 2.35–2.23 (m, 2H),
2.14–1.92 (m, 5H), 1.92–1.80 (m, 2H), 1.79–1.56 (m, 1H), 1.53–
1.36 (m, 2H), 1.39–1.21 (m, 2H); 13C NMR (100 MHz, DMSO-d6)
δ 160.2 (2), 134.5, 129.3 (2), 128.7(2), 128.6 (4), 126.7 (2), 125.5,
115.4, 115.1, 114.9 (4), 54.7, 53.0, 51.5, 50.8, 48.6, 44.1, 34.5, 26.5,
26.0, 24.9, 21.7, 20.8, 17.4, 15.1; HR-MS: Calcd. for C34H37N2F2Cl
[MþH]þ, 547.2686, Found, 547.2686.
4.1.2.3. -40,40-diethyl sophoridinene bihydrochloride (7b). Com-
pound 7a was obtained from ethylmagnesium bromide and 4
stirring at reﬂuxing temperature following the similar procedures
with 6 and acidiﬁcation by HCl/diethyl ether as a white solid.
Yield: 40%, m.p.: 77–79 1C; 1H NMR (500 MHz, DMSO-d6) δ
11.67 (s, 1H), 11.20 (s, 1H), 8.29–7.79 (m, 2H), 7.66–7.19 (m,
2H), 4.62–4.47 (m, 4H), 4.46–4.33 (m, 1H), 4.31–4.09 (m, 1H),
3.96–3.67 (m, 1H), 3.35–3.23 (m, 2H), 3.23–3.02 (m, 3H), 3.01–
2.79 (m, 1H), 2.77–2.54 (m, 1H), 2.51–2.43 (m, 1H), 2.02–1.77
(m, 5H), 1.78–1.61 (m, 5H), 1.61–1.29 (m, 4H), 0.94–0.84 (m,
4H), 0.84–0.67 (m, 2H); 13C NMR (126 MHz, DMSO-d6) δ 143.6,
140.4 (2), 134.1 (2), 132.4, 128.8, 117.3, 80.1, 60.3, 55.0, 54.3,
51.5, 44.0 (2), 38.8, 32.4, 25.4, 24.6, 22.1, 21.1, 17.0, 12.9, 12.4,
8.5 (2); HR-MS: Calcd. for C26H39N2Cl·2HCl [M–2HClþH]þ,
415.2874, Found, 415.2871.
4.1.3. 12-N-p-Chlorobenzyl sophoridinic hemiacetal (10)
A dry, 250-mL, three-necked, round-bottomed ﬂask equipped with
a magnetic stirrer and a dropping funnel was charged with 100 mL
of dry dichloromethane under an atmosphere of nitrogen. After
cooling to 78 1C, oxalyl chloride (1.0 mL, 12 mmol ) and dry
dimethyl sulfoxide (1.5 mL, 20 mmol) were added dropwise to the
stirred solution. After 5 min, 8 (3.7 g, 10 mmol) in 20 mL of
dichloromethane was added with stirring. The mixture was stirred
for an additional 0.5 h at 78 1C, and freshly distilled triethyla-
mine (5.6 mL, 40 mmol) was added. The mixture was then
allowed to warm to room temperature over 0.5 h, whereupon
50 mL of water is added. The phases are separated, and the
aqueous phase is extracted three times with 50 mL of diethyl ether
or dichloromethane. The combined organic phases were washed
successively with water (50 mL) and brine (50 mL). The organic
layer was dried over anhydrous magnesium sulfate, and the solvent
was removed under reduced pressure, and the residue was
puriﬁed by ﬂash column chromatography on silica gel with
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viscous solid, to which 1 mol/L hydrochloric acid-methanol
solution (10 mL) was added and stirred at room temperature for
10 min, removal of the solvent generated target compound 10 as a
white solid. Yield: 67%, m.p.: 64–66 1C; 1H NMR (500 MHz,
CD3OD) δ 7.38–7.28 (m, 4 H), 4.91 (s, 3H), 3.68–3.46 (m, 2H),
3.20–3.05 (m, 1H), 3.00–2.74 (m, 2H), 2.65–2.46 (m, 1H), 2.39–
2.28 (m, 1H), 2.25–1.97 (m, 4H), 1.94–1.69 (m, 4H), 1.72–1.48
(m, 6H), 1.47–0.94 (m, 6H); 13C NMR (126 MHz, CD3OD) δ
140.2, 133.4, 131.0 (2), 129.2 (2), 99.6, 65.0, 64.9, 60.2, 58.9,
55.1, 52.6, 46.2, 39.1, 30.2, 28.4, 26.4, 26.0, 23.8, 23.7, 23.5,
20.0; HR-MS: Calcd. for C23H35O2N2Cl [MþH]þ, 407.2459,
Found, 407.2459.
4.1.4. 12-N-p-lorobenzyl sophoridinic hydroxyl oxime
bihydrochloride (11)
To a mixture of hydroxylamine hydrochloride (0.25 g, 3.6 mmol)
in 20% sodium hydroxide solution (70 mL), 9 (1.1 g, 3.0 mmol)
was added and the mixture was stirred at room temperature until
TLC analysis showed the completion of the reaction. The insoluble
solid was ﬁltered off and the solvent was removed by condensa-
tion, and the residue was puriﬁed by ﬂash column chromatography
on silica gel with CH2Cl2/CH3OH as the eluents to obtain the free
form of 11 as colorless oil, which was then acidiﬁed by 3 mol/L
HCl/ether (10 mL) to afford 11 as a white solid. Yield: 72%, m.p.:
91–92 1C; 1H NMR (500 MHz, DMSO-d6) δ 10.81 (s, 1H), 10.44
(s, 1H), 7.53–7.14 (m, 4H), 3.64–3.48 (m, 2H), 3.42–3.33 (m, 3H),
3.22–3.05 (m, 2H), 3.01–2.89 (m, 1H), 2.66–2.57 (m, 1H), 2.41–
1.97 (m, 7H), 1.93–1.71 (m, 3H), 1.68–1.33 (m, 6H), 1.32–1.14
(m, 2H); 13C NMR (126 MHz, DMSO-d6) δ 149.7, 139.3, 131.7,
130.3 (2), 128.6 (2), 63.2, 58.9, 57.3, 50.3, 44.6, 35.5, 29.6, 27.9,
26.5, 25.1, 24.4, 23.0, 22.8, 22.3, 18.1; HR-MS: Calcd. for
C22H32ON3Cl·2HCl [M–2HClþH]þ, 390.2306, Found, 390.2305.
4.1.5. 12-N-p-Chlorobenzyl sophoridinic methyl ether (12)
To a solution of free 11 (1.95 g, 5.0 mmol) in anhydrous THF
(50 mL) under nitrogen, methyl benzenesulfonate (2.64 g,
20.0 mmol) was added. The mixture was stirred at room tempera-
ture until TLC analysis showed the completion of the reaction.
The reaction was quenched by methanol (5 mL), and condensed,
the residue was puriﬁed by ﬂash column chromatography on silica
gel with CH2Cl2/CH3OH as the eluents to obtain the free form of
12 as a yellow solid. Yield: 57%, m.p.: 83–85 1C; 1H NMR
(400 MHz, DMSO-d6) δ 7.49–7.14 (m, 5H), 3.52 (s, 3H), 3.42–
3.23 (m, 3H), 3.23–3.02 (m, 2H), 3.03–2.91 (m, 1H), 2.76–2.56
(m, 1H), 2.43–1.89 (m, 7H), 1.91–1.65 (m, 4H), 1.71–1.36 (m,
6H), 1.34–0.99 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 150.6,
149.7, 139.3, 131.7, 130.3 (2), 128.6 (2), 63.2, 59.0, 57.3, 52.2,
50.3, 44.6, 35.6, 29.6, 27.9, 26.5, 24.4, 23.0, 22.8, 22.3, 18.1; HR-
MS: Calcd. for C23H34ON3Cl [MþH]þ, 404.2463, Found,
404.2482.
4.1.6. 12-N-p-Chlorobenzyl-40-N-morpholin-sophoridinic
imine (13)
To a mixture of 9 (1.1 g, 3.0 mmol) in anhydrous methanol
(50 mL), 4-amine-morpholin (0.43 mL, 4.5 mmol) was added and
the mixture was reﬂuxed for 4 h before cooled to room temperature.
The solvent was condensed and dichloromethane (50 mL) was
added, and the mixture was washed successively with water
(30 mL) and saturated ammonium chloride solution (30 mL). The
mixture was evaporated and the residue was puriﬁed by ﬂashcolumn chromatography on silica gel with CH2Cl2/CH3OH as the
eluents to obtain the target compound 13 as a white solid. Yield:
74%, m.p.: 59–61 1C; 1H NMR (500 MHz, DMSO-d6) δ 7.38–7.30
(m, 4H), 6.93 (t, J¼5.2 Hz, 1H), 3.73–3.65 (m, 4H), 3.61–3.44 (m,
2H), 3.01–2.89 (m, 1H), 2.88–2.75 (m, 6H), 2.71–2.60 (m, 1H),
2.50–2.35 (m, 2H), 2.25–1.87 (m, 6H), 1.82–1.62 (m, 3H), 1.58–
1.37 (m, 5H), 1.31–1.21 (m, 2H), 1.17–1.10 (m, 1H), 1.01 (dd,
J¼20.5, 11.7 Hz, 1H); 13C NMR (126 MHz, DMSO-d6) δ 140.4,
139.7, 131.4, 130.2 (2), 128.5 (2), 66.1 (2), 63.9, 58.5, 57.7, 54.4,
52.5 (2), 52.4, 51.6, 45.4, 38.0, 32.9, 29.8, 26.8, 26.1, 25.5, 22.6,
19.2; HR-MS: Calcd. for C26H39ON4Cl [MþH]þ, 459.2885,
Found, 459.2885.
4.1.7. General procedures for the synthesis of 14
4.1.7.1. 12-N-p-Chlorobenzyl-40-(4-chloro-3-triﬂuoromethylphe-
nyl)sophoridinic amine trihydrochloride (14a). To a mixture of 9
(1.1 g, 3.0 mmol) in anhydrous methanol (50 mL), 4-chloro-3-
triﬂuoromethylphenylamine (0.8 g, 4.5 mmol) was added and the
mixture was reﬂuxed for 4 h, then sodium cyanoborohydride
(0.9 g, 4.5 mmol) was added portion wise, and the mixture was
reﬂuxed for another 4 h. The mixture was cooled to room
temperature and evaporated, then dichloromethane (50 mL) was
added, and the mixture was washed successively with water
(30 mL) and saturated ammonium chloride solution (30 mL).
The mixture was evaporated and the residue was puriﬁed by ﬂash
column chromatography on silica gel with CH2Cl2/CH3OH as the
eluents, then acidiﬁed by 3 mol/L HCl/ether (10 mL) and ﬁltrated
to obtain the target compound 14a as a white solid. Yield: 68%,
m.p.: 71–73 1C; 1H NMR (500 MHz, DMSO-d6) δ 11.55 (s, 1H),
11.12 (s, 1H), 10.93 (s, 1H), 8.12–7.77 (m, 2H), 7.01 (d,
J¼8.7 Hz, 3H), 6.91–6.74 (m, 2H), 4.52–4.34 (m, 1H), 4.34–
4.12 (m, 1H), 3.88–3.69 (m, 1H), 3.65–3.25 (m, 4H), 3.24–2.76
(m, 3H), 2.76–2.55 (m, 3H), 2.43–1.98 (m, 2H), 1.99–1.29 (m,
8H), 1.29–1.14 (m, 2H), 1.03–0.79 (m, 1H); 13C NMR (126 MHz,
DMSO-d6) δ 153.9, 146.3, 139.7, 131.5, 130.4, 130.2, 128.9 (2),
128.5 (2), 90.3, 64.1, 60.6, 58.6, 57.7, 56.0, 54.2, 51.5, 45.4, 43.6,
37.8, 30.2, 29.5, 26.9, 25.5, 25.4, 23.1, 23.1, 19.1; HR-MS: Calcd.
for C29H36N3F3Cl2·3HCl [M–3HClþH]þ, 554.2311, Found,
554.2313.
4.1.7.2. 12-N-p-Chlorobenzyl-40-(N-methypiperazine)sophoridinic
amine tetrahydrochloride (14b). Compound 14b was obtained from
N-methypiperazine and 9 following the similar procedure with 14a.
Yield: 65%, m.p.: 73–75 1C; 1H NMR (500 MHz, DMSO-d6) δ
12.25 (s, 1H), 12.15 (s, 1H), 11.61 (s, 1H), 11.16 (s, 1H), 7.99 (d,
J¼7.9 Hz, 2H), 7.57 (d, J¼7.9 Hz, 2H), 5.07 (s, 3H), 4.50–4.16 (m,
1H), 3.92–3.68 (m, 3H), 3.66–3.35 (m, 5H), 3.34–2.75 (m, 11H),
2.73–2.53 (m, 2H), 2.21–1.58 (m, 9H), 1.60–1.23 (m, 3H), 1.16–0.99
(m, 1H), 1.01–0.80 (m, 1H); 13C NMR (125 MHz, DMSO-d6) δ
134.7, 133.1, 129.5 (2), 129.2 (2), 65.3, 60.9, 55.5, 55.0, 52.1 (2),
51.9 (2), 49.9, 48.5, 44.6, 42.5, 26.1, 25.1, 23.0, 22.8, 22.3, 21.9,
21.7, 17.6, 15.6; HR-MS: Calcd. for C27H43N4Cl·4HCl
[M–4HClþH]þ, 459.3249, Found, 459.3249.
4.2. Biological evaluation
4.2.1. MTT assay
The human tumor cell lines, HepG2 and MCF-7, were obtained
from American Type Culture Collection. Cells were routinely
cultured in the MEM-EBSS medium (Hyclone, UT) with 10%
FBS (Gibco, USA) and 1% penicillinestreptomycin and incubated
at 37 1C with 5% CO2. Cells were counted and plated at a density
Chongwen Bi et al.228of 4000 cells per well in 96-well plates. After 24 h, cells were
treated with different compounds at different concentrations for
48 h. The effect on cell growth inhibition was determined by the
MTT assay as previous described. The growth inhibition rate (%)
was calculated at each concentration and IC50 value was calculated
with Sigmaplot software. Results were obtained from triplicate
determinations and shown as mean7SD.
4.2.2. Cell cycle distribution assay
HepG2 cells were treated with 5a at different concentrations for
24 h and then cells were harvested. Cells were ﬁxed with 70%
ethanol and stored at –20 1C overnight. The ﬁxed cells were
incubated with 200 μg/mL RNase at 37 1C for 30 min and then
stained with 50 μg/mL propidium iodide in the dark for 30 min.
Cell cycle distribution was then analyzed by ﬂow cytometry using
FACS analysis (BD FACSCalibur, USA).
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